Ibrutinib plus venetoclax in relapsed/refractory CLL: results of the Bloodwise TAP CLARITY study
Authors
Hillmen, PRawstron, A
Brock, K
Vicente, M
Yates, F
Bishop, R
Macdonald, D
Fegan, C
McCaig, A
Schuh, A
Pettitt, A
Gribben, G
Patten, M
Devereux, S
Bloor, Adrian
Fox, P
Forconi, F
Munir, T
Affiliation
Department of Haematology, Cardiff University, CardiffIssue Date
2018
Metadata
Show full item recordCitation
Hillmen P, Rawstron A, Brock K, Vicente S, Yates F, Bishop R, et al. Ibrutinib plus venetoclax in relapsed/refractory CLL: results of the Bloodwise TAP CLARITY study. Blood. 2018;132.Journal
BloodDOI
10.1182/blood-2018-182Additional Links
https://dx.doi.org/10.1182/blood-2018-182Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2018-182